跳至主要内容
临床试验/ACTRN12610000434099
ACTRN12610000434099已完成4 期

Modified HM3 versus Modulith SLX-F2 lithotripter: A prospective randomized trial to compare the clinical efficacy and complication rate between the first and the latest lithotriptor generation in patients with kidney and/or ureteral stones.

Department of Urology0 个研究点目标入组 800 人开始时间: 2010年5月28日最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
800

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Open (masking not used)

入排标准

年龄范围
o limit 至 o limit(—)
性别
All

入选标准

  • Every patient requiring extracorporeal shock wave lithotripsy after written informed consent.

排除标准

  • Patients referred for treatment with HM3. After prior unsuccessful extracorporeal shock wave lithotripsy for the same stone in another hospital. Patients with staghorn calculi or stones with a diameter larger than 30mm. In case of technical problems with the randomly assigned lithotripter on the day of intervention or impossibility to localize the calculus with the randomly assigned lithotripter.
  • Thrombocytes <100x10/9 per L, prothrombin time < 60%, pregnancy, urinary tract infection, intake of non-steroidal anti-inflammatory drugs within the last 48 hours or ingestion of platelet inhibiting agents within the last 7-10 days.

研究者

相似试验